Reinicio de anticoagulación después de hemorragia intracraneal: evidencia actual y toma de decisiones clínicas
Resumen
Introducción: La hemorragia intracraneal (HIC) en pacientes bajo terapia anticoagulante representa una de las emergencias neurológicas más desafiantes en la práctica clínica contemporánea. La decisión de reiniciar la anticoagulación tras una HIC enfrenta la paradoja de optimizar simultáneamente la prevención tromboembólica y la minimización del riesgo hemorrágico recurrente. Objetivo: Sintetizar la evidencia disponible sobre el momento óptimo, los criterios de selección de candidatos y los marcos de toma de decisiones para el reinicio de anticoagulación oral tras HIC, con énfasis en fibrilación auricular y anticoagulantes de acción directa. Métodos: Revisión narrativa con búsqueda bibliográfica estructurada en PubMed/MEDLINE, EMBASE, Cochrane Library y LILACS (enero 2010 – marzo 2025), complementada con actualización manual hasta marzo 2026 para ensayos clínicos recientes. La síntesis narrativa se organizó por dimensiones temáticas predefinidas. Se priorizaron ensayos clínicos aleatorizados, metaanálisis con datos individuales de pacientes, cohortes prospectivas de alta calidad y guías vigentes (AHA/ASA 2022, ESC 2024, EHRA 2021, ISTH 2022). La calidad metodológica se evaluó con Newcastle-Ottawa para estudios observacionales y RoB 2.0 para ensayos aleatorizados. Resultados: Los ensayos RESTART, APACHE-AF y OAC-ICH aportan evidencia de nivel moderado a alto sobre la seguridad y eficacia del reinicio de anticoagulación en pacientes con HIC y fibrilación auricular. El reinicio entre las semanas 4–8 postcicatrización parece asociarse con reducción del riesgo trombótico sin incremento significativo del riesgo hemorrágico recurrente, especialmente con anticoagulantes de acción directa (ACOD). La localización de la HIC (lobar vs. profunda), la presencia de angiopatía amiloide cerebral, el control de la hipertensión arterial y la puntuación de riesgo tromboembólico (CHA₂DS₂-VASc ≥2) son determinantes críticos de la decisión clínica.Conclusiones: El reinicio de anticoagulación postcHIC en pacientes seleccionados con fibrilación auricular y alto riesgo embólico ofrece beneficio neto cuando se integra bajo un enfoque multidisciplinario, protocolo estructurado de neuroimagen seriada y control estricto de factores de riesgo modificables. Los ACOD son la opción preferida sobre antagonistas de vitamina K cuando no existen contraindicaciones estructurales.
Descargas
Citas
RESTART Collaboration. Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial. Lancet. 2019;393(10191):2613-2623. doi:10.1016/S0140-6736(19)30840-2
Schreuder FHBM, van Nieuwenhuizen KM, Hofmeijer J, et al; APACHE-AF Trial Investigators. Apixaban versus antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intracerebral haemorrhage in patients with atrial fibrillation in the Netherlands (APACHE-AF): a randomised, open-label, phase 2 trial. Lancet Neurol. 2021;20(11):907-916. doi:10.1016/S1474-4422(21)00298-2
Veltkamp R, Korompoki E, Harvey KH, et al; PRESTIGE-AF Investigators. Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2025;405(10482):927-936. doi:10.1016/S0140-6736(25)00333-2
Al-Shahi Salman R, Stephen J, Tierney JF, et al; COCROACH Collaboration. Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials. Lancet Neurol. 2023;22(12):1140-1149. doi:10.1016/S1474-4422(23)00315-0
RESTART Collaboration. MRI-RESTART substudy: brain MRI findings and outcomes of resuming antithrombotic treatment after intracranial bleeding. Lancet Neurol. 2023;22(5):404-414. doi:10.1016/S1474-4422(23)00047-0
Shoamanesh A, Tsai J, Siddiqui M, et al. OAC-ICH Trial: Oral Anticoagulation in Intracerebral Hemorrhage Survivors — design and rationale. Eur Stroke J. 2021;6(3):265-274. doi:10.1177/23969873211028125
Korompoki E, Heuschmann P, Harvey KH, et al. Prevention of stroke in intracerebral haemorrhage survivors with atrial fibrillation: rationale and design for PRESTIGE-AF trial. Thromb Haemost. 2025;125(4):395-403. doi:10.1055/a-2496-5492
Papageorgiou NM, Palaiodimou L, Theodorou A, et al. Safety and efficacy of oral anticoagulation in patients with intracranial hemorrhage and atrial fibrillation: a systematic review and meta-analysis of randomized controlled clinical trials. Ther Adv Neurol Disord. 2025. doi:10.1177/17562864251406065
Kaisaier W, Guan C, Ye M, et al. Effect of oral anticoagulant therapy on adverse outcomes in patients with atrial fibrillation after intracranial hemorrhage. Heart Rhythm. 2025;22(11):2836-2844. doi:10.1016/j.hrthm.2025.06.023
Zhang G, Wu Y, Gao L, et al. Oral anticoagulant therapy in patients with atrial fibrillation after intracranial hemorrhage: a meta-analysis of randomized controlled trials. Clin Appl Thromb Hemost. 2025. doi:10.1177/10760296251368889
Wu YH, Lin SY, Lin FJ, Tang SC, Wang CC. Outcomes of reinitiating direct oral anticoagulants after intracranial hemorrhage: a sequential target trial emulation study. JACC Asia. 2025;5(3):361-370. doi:10.1016/j.jacasi.2024.11.008
D'Anna L, Prandin G, Pirera E, et al. Timing and safety of anticoagulation reinitiation after intracranial hemorrhage in patients with mechanical valves: a meta-analysis. Neurology. 2025;105(8):e214184. doi:10.1212/WNL.0000000000214184
Murthy SB, Gupta A, Merkler AE, et al. Restarting Anticoagulant Therapy After Intracranial Hemorrhage: A Systematic Review and Meta-Analysis. Stroke. 2017;48(6):1594-1600. doi:10.1161/STROKEAHA.116.016327
Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2022;53(7):e282-e361. doi:10.1161/STR.0000000000000407
Van Gelder IC, Rienstra M, Bunting KV, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-3414. doi:10.1093/eurheartj/ehae176
Shoamanesh A, Klijn CJM, Sheth KN, et al. Oral anticoagulation following intracranial haemorrhage in patients with atrial fibrillation. Eur Stroke J. 2025;10(1_suppl):35-45. doi:10.1177/23969873241296803
Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612-1676. doi:10.1093/europace/euab065
Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2022;162(5):e207-e243. doi:10.1016/j.chest.2022.07.025
Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-1151. doi:10.1056/NEJMoa0905561
Granger CB, Alexander JH, McMurray JJV, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992. doi:10.1056/NEJMoa1107039
Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891. doi:10.1056/NEJMoa1009638
Giugliano RP, Ruff CT, Braunwald E, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093-2104. doi:10.1056/NEJMoa1310907
Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962. doi:10.1016/S0140-6736(13)62343-0
Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137(2):263-272. doi:10.1378/chest.09-1584
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. Chest. 2010;138(5):1093-1100. doi:10.1378/chest.10-0134
Vidal-Jordana A, Pelizzari L, Targa Fabelo H, et al. CAVE score for intracerebral hemorrhage: validation and impact on anticoagulant resumption decisions. J Neurol Neurosurg Psychiatry. 2023;94(5):389-395. doi:10.1136/jnnp-2022-330022
Charidimou A, Boulouis G, Frosch MP, et al. The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRI-neuropathology diagnostic accuracy study. Lancet Neurol. 2022;21(8):714-725. doi:10.1016/S1474-4422(22)00208-3
Al-Shahi Salman R, Frantzias J, Lee RJ, et al. Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data. Lancet Neurol. 2018;17(10):885-894. doi:10.1016/S1474-4422(18)30253-9
Rodrigues MA, Samarasekera N, Lerpiniere C, et al. The Edinburgh CT and genetic diagnostic criteria for lobar intracerebral haemorrhage associated with cerebral amyloid angiopathy: model development and diagnostic test accuracy study. Lancet Neurol. 2018;17(3):232-240. doi:10.1016/S1474-4422(18)30006-1
An SJ, Kim TJ, Yoon BW. Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update. J Stroke. 2017;19(1):3-10. doi:10.5853/jos.2016.00864
Feigin VL, Krishnamurthi RV, Parmar P, et al. Update on the Global Burden of Ischemic and Hemorrhagic Stroke in 1990-2013: The GBD 2013 Study. Neuroepidemiology. 2015;45(3):161-176. doi:10.1159/000441085
Shoamanesh A, Al-Shahi Salman R, Cordonnier C, et al; ENRICH-AF Steering Committee. Anticoagulation in patients with cerebral amyloid angiopathy [ENRICH-AF DSMB safety communication]. Lancet. 2023;402(10417):2017-2019. doi:10.1016/S0140-6736(23)02025-1
Eilertsen HLK, Sandset EC, Forfang E, et al. Should antithrombotic treatment be prescribed after an intracerebral haemorrhage? — main results from the study of antithrombotic treatment after intracerebral haemorrhage (STATICH). Presented at: European Stroke Organisation Congress (ESOC), 21-23 May 2025, Helsinki, Finland. 2025
Kuramatsu JB, Sembill JA, Gerner ST, et al. Management of therapeutic anticoagulation in patients with intracerebral haemorrhage and mechanical heart valves. Eur Heart J. 2018;39(19):1709-1723. doi:10.1093/eurheartj/ehy056
Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304. doi:10.1136/annrheumdis-2019-215213
Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132(13):1365-1371. doi:10.1182/blood-2018-04-848333
Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease. J Am Coll Cardiol. 2017;70(2):252-289. doi:10.1016/j.jacc.2017.03.011
Biffi A, Kuramatsu JB, Leasure A, et al. Oral Anticoagulation and Functional Outcome after Intracerebral Hemorrhage. Ann Neurol. 2017;82(5):755-765. doi:10.1002/ana.25079
Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015;313(8):824-836. doi:10.1001/jama.2015.0846
Nielsen PB, Larsen TB, Skjøth F, Gorst-Rasmussen A, Rasmussen LH, Lip GYH. Restarting Anticoagulant Treatment After Intracranial Hemorrhage in Patients With Atrial Fibrillation and the Impact on Recurrent Stroke, Mortality, and Bleeding. Circulation. 2015;132(6):517-525. doi:10.1161/CIRCULATIONAHA.115.015735
Biffi A, Anderson CD, Battey TW, et al. Association between blood pressure control and risk of recurrent intracerebral hemorrhage. JAMA. 2015;314(9):904-912. doi:10.1001/jama.2015.10082
Korompoki E, Filippidis FT, Nielsen PB, et al. Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. Neurology. 2017;89(7):687-696. doi:10.1212/WNL.0000000000004235
Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med. 2015;373(25):2413-2424. doi:10.1056/NEJMoa1510991
Pollack CV Jr, Reilly PA, Weitz JI. Dabigatran Reversal with Idarucizumab. N Engl J Med. 2017;377(5):431-441. doi:10.1056/NEJMoa1707460
Seiffge DJ, Werring DJ, Paciaroni M, et al. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. Lancet Neurol. 2019;18(1):117-126. doi:10.1016/S1474-4422(18)30356-9
Chi KY, Chang Y, Lee PL, Lin YS, Nanna MG. Intracranial haemorrhage: sex, age, and treatment considerations. Lancet. 2025;406(10513):1728-1729. doi:10.1016/S0140-6736(25)01260-7
Derechos de autor 2026 Gustavo Andres Diaz Cruz , Juan Camilo Mejia Villalobos, Yusneht Grein Castrillon Moscote , Carlos Alberto Jurado Ortega , Laura Fernanda Cardona Rubio , María Isabela Gómez Lopez , Ana Lucía Gómez López , Daniel Gilberto González Santos , Liliana Cristina Diaz Cruz , Jorge Eduardo Vega Parra , Miguel Ángel Saza Moreno , Wendy Katherine rey vega
Esta obra está bajo licencia internacional Creative Commons Reconocimiento 4.0.
.png)
.png)
1.png)
